Putnam is pleased to announce the promotion of Joia Ramchandani and Ben Diop to Principal. Both have made major contributions to broadening the firm’s capabilities, further enhancing our impact for clients, and continuing to build Putnam’s unique culture.
“We congratulate them on their success and are excited to see the significant contributions these leaders will continue to make as they advance in their careers.” said Remco op den Kelder, Partner & Boston Office Head.
Joia Ramchandani serves clients in immunology, rare disease, oncology, and vaccines. Her recent focus has been on product positioning and market opportunity identification for late-stage clinical pipeline products as well as for marketed products. She has extensive experience in assessing and translating complex clinical product attributes into commercial success. In her work, she has collaborated across a broad range of global healthcare stakeholders – national policy-makers, physicians, managed care providers, advocacy groups – to derive actionable insights for clients. She earned her MBA from Harvard Business School, a participant in Putnam’s MBA sponsorship program for high-achieving employees. She earned her B.S. in Chemical-Biological Engineering from MIT, where she also concentrated in Creative Writing.
Benjamin Diop serves prominent life-science and VC/PE clients in market opportunity assessments, global reimbursement strategies, therapeutic area strategies, and franchise growth strategies. He has extensive experience leading product launch projects and the associated development of value stories in support of physician adoption and market access. These projects often include detailed forecasting and market modeling that leverages multiple complex data sets – claims data, prescription data, primary physician research, anonymized patient records, epidemiology analysis and clinical trial results. Ben has made especially strong contributions to Putnam’s hematology and oncology work, where he has developed deep expertise in multiple myeloma, many types of leukemia, and myelofibrosis on the hematology side, and pancreatic, lung, breast, and brain tumors on the solid tumor side. He has also supported leading franchises in cardiovascular and infectious disease. He earned his PhD from the joint Harvard-MIT Division of Health Sciences and Technology, where his research focused on drug delivery